SARASOTA, Fla., Oct. 5, 2004 (PRIMEZONE) -- The following is an investment opinion issued by eLocity Inc.:
Fidelis Energy, Inc. (OTCBB:FDEI), Siebel Systems, Inc. (Nasdaq:SEBL), Cytyc Corporation (Nasdaq:CYTC) and Medarex, Inc. (Nasdaq:MEDX).
Making ground is oil and gas company Fidelis Energy, Inc. (OTCBB:FDEI). Fidelis announced after the closing bell Monday, "that the steam flood of the 2nd well at the Comanche Point heavy oil project is set to commence. The company plans to inject 5,000 barrels of steam into the well through the 5 mmbtu/hr steam generator over the next 10 days to heat the oil prior to pump testing to evaluate oil flow rates."
Fidelis Energy plans to steam a number of the 19 wells on the property to increase to the heavy oil daily production at Comanche.
FDEI is currently seeing its price rise from around .75 a week or so prior to around $1.35 a share.
On the Nasdaq;
Siebel Systems, Inc. (Nasdaq:SEBL)
Siebel Systems, Inc. and IBM (NYSE:IBM) announced after the bell Monday an expansion of their global strategic alliance focused on Siebel Business Analytics at the Siebel Business Intelligence Summit in Los Angeles.
The companies announced cooperation in the design of the new Siebel Enterprise Analytic Applications introduced Monday, leveraging IBM subject matter expertise and best practices for supply chain, financial management, workforce management and strategic sourcing business practices.
SEBL closed Monday's regular trading session up 1.15 at $9.34, on volume of 39,831,048 shares, over 4 1/2 times its average daily volume.
Cytyc Corporation (Nasdaq:CYTC)
Diagnostic services provider, Cytyc Corporation, announced on Monday a multiyear agreement to place ThinPrep(r) Imaging Systems within LabOne, Inc.'s (Nasdaq:LABS) laboratory in the Greater Kansas City area. Cytyc Corp. said this LabOne location is the highest volume, single-site testing laboratory in the country and provides diagnostic healthcare testing to physicians, hospitals, managed care organizations and employers nationwide.
CYTC ended Monday's trading session at $25.225, up 1.295 on above average volume of 2,162,781 shares.
Medarex, Inc. (Nasdaq:MEDX)
Biopharmaceutical company Medarex, Inc. announced Monday that it has been given two grants from the National Institute of Allergy and Infectious Diseases, for the research and development of MDX-1303, a human antibody for use against human anthrax infection. The grants are likely to total approximately $7.2 million over the next three years, if all performance milestones are met, Medarex said.
MEDX closed Monday's trading session at $7.88, up 0.21 on volume of 1,243,547 shares.
About eLocity Inc: eLocity owns and operates three financial websites for investors.
-PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.
-StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers". We rank stocks on volume, message board activity, sentiment and trend forecast.
-Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.
Sign up for FREE at any of the sites above.
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, here after referred to as "the company". The company received compensation for newsletter services for Fidelis Energy (public company). The compensation is twenty five thousand dollars and earlier received eight thousand dollars for prior services all from a non-affiliated third party Knights Bridge Captial Corp. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.
The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investing in the public company that this newsletter is providing service for should be viewed as speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.
The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.